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Table 1
Protein antigen Research data
Pneumococcal surface protein A (PspA) Protective aganist multiple pneumococcal
serotypes in mice models of invasive disease
pneumonia, and colonization. Vaccination of
healthy volunteers with PspA generated
antibodies aganist multiple strains that protected
mice aganist invasive disease. Human studies in
progess.
Pneumolysins.Pneumolysoids Protection aganist Pneuminia and increased
survival after intraperitoneal challenge. human
studies in progress
Neuraminidases (Nan) Protection aganist colonization and otitis media
Pneumococcal surface protein C (PspC) Protection aganist colonization. Protection aganist
sepsis
Pneumococcal protective protein A (PppA) Protection aganist lung infection. Protective
aganist nasopharyngeal colonization.
Pneumococcal Histidine Trial Protein D Protective aganist animal models of invasive
disease and pneumonia phase II trial reports
awaited.
IC4 antigens Protection aganist sepsis, pneumonia,
nasopharyngeal carriage.
Conclusion: Despite gaps in knowledge, Pneumococcal Protein
Vaccines could be an efﬁcacious, effective and economic alterna-
tive to currently available Pneumococcal Conjugate Vaccines for
the control of pneumococcal infections.
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Background: In 2012 the UK experienced a national outbreak
of pertussis. The highest rates of infections were seen in infants
aged less than 3months and therewere 14 deaths in this age group
attributable to pertussis. This outbreak prompted the Department
of Health (DH) to introduce a temporary vaccination programme
for pregnant women with the aim of preventing infections in very
young infants.
This survey aimed to estimate pertussis vaccine uptake in
pregnant women and describe variations according to age, ethnic-
ity, parity and location. Informationwas also gathered on inﬂuenza
vaccine uptake.
Methods & Materials: This was a cross–sectional survey of vac-
cine uptake amongwomendelivering inmaternity units in England
over a ﬁve-day period during April and May 2013. The target sam-
ple size was at least 380 women from maternity units throughout
the country. Units were asked to complete surveys alongside birth
paperwork for all women delivering a live birth during the 5 day
period. Proportions vaccinated were calculated with 95% conﬁ-
dence intervals and multiple logistic regression used to assess
differences in uptake.
Results: Twenty–nine trusts participated in the survey, retur-
ning 1325 surveys, 85% of which contained information about
vaccine uptake. Pertussis vaccine uptake was 52.6% (range 18.1%
to 72.4%). Inﬂuenza vaccine uptake was 52.2% (range 29.0% to
70.1%). Uptake of both vaccines was signiﬁcantly higher in the
White British ethnic group than in any other at 60% (95% CI 56%
- 62%). Women in the most deprived quintile were least likely to
have had either vaccine (pertussis vaccine OR v’s least deprived
0.44, 95%CI 0.28–0.67/inﬂuenza vaccineOR0.56, 95%CI 0.36–0.86).
Ninety–eight per cent of this sample received the pertussis vaccine
within the recommended 28–38 weeks gestation timeframe.
Conclusion: The results of this survey indicate that vaccine
uptake rates in pregnant women vary signiﬁcantly across regions
and are affected by factors such as ethnicity and deprivation.
Every opportunity should be taken to promote both pertussis and
inﬂuenza vaccines to pregnant women.
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Background: Noroviruses (NoVs) are the leading cause of acute
infectious gastroenteritis worldwide and are highly contagious.
Although commonly associatedwith contaminated food andwater,
the majority of outbreaks reported in the United States are a result
of person-to-person transmission. Vomitingmay play a critical role
in person-to-person transmission. Since environmental contami-
nation resulting from episodes of vomiting have been implicated
in norovirus outbreaks, a strategy to reduce norovirus-associated
vomiting would have public health beneﬁt.
Methods & Materials: Healthy adult subjects age 18-49 were
randomized equally to two study groups to either receive two
intramuscular injected doses of an investigational norovirus biva-
lent GI.1/GII.4 VLP vaccine or saline placebo on study days 1 and
28. On study day 56, 109 subjects were admitted to an in-patient
unit and administered an oral dose of 4.4×103 PCR units of a live
GII.4 norovirus; 56 vaccine recipients and 53 saline placebo recipi-
